Scale or Stale – Realizing the true value of Gen AI in life sciences

We are delighted to extend this exclusive invitation to join us for a transformative Life Sciences event at Moltkes Palæ on May 14th

We are standing at the forefront of a new era propelled by the convergence of Generative AI and Language Models. These transformative technologies hold the promise of redefining the industry’s paradigms, igniting new avenues of discovery and efficacy, and empowering Life Sciences organizations to navigate uncharted territories with confidence and efficiency.

Numerous industry studies underscore the necessity for Life Sciences organizations to integrate Generative AI into their core operations, highlighting AI’s pivotal role in sustaining competitiveness within a rapidly evolving and complex market. However, akin to any transformative technology, the true value of GenAI and AI emerges at scale and when directly aligned with the strategic objectives of the business. This raises the pertinent question: How can we ensure that our pilots and POCs don’t stale, but rather scale?

“The risk with generative
AI is not that leaders fail
to try it, but that trying is
as far as they get. “

Harvard Business
Review, Dec 01,2023

Find the program below and join us as we, together with our guests, shed light on the path forward.

Best Regards
John Fodeh – VP, Life Sciences & MedTech